| Hypertensive nephropathy: prevention and treatment recommendations. | |
| | |
MedLine Citation:
|
PMID: 20718588 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: A worldwide epidemic of chronic kidney disease (CKD) exists; hypertensive nephropathy is second only to diabetes as a leading cause of progressive CKD. Due to the increasing morbidity and mortality and escalating costs associated with end-stage renal disease (ESRD), novel therapeutic strategies are needed urgently to maximally reduce albuminuria, control blood pressure, and delay progression of hypertensive nephropathy to ESRD. In particular, rational use of renin-angiotensin-aldosterone (RAAS) blockers and achieving blood pressure targets are crucial to reduce cardiovascular and renal outcomes. AREAS COVERED IN THIS REVIEW: We discuss the pathophysiology of hypertensive nephropathy and review current research evidence in support of i) albuminuria reduction as a key factor to maximally slow CKD progression, ii) the blood pressure (BP) goal of < 130 mmHg, and iii) strategies for prevention and optimal treatment of hypertensive nephropathy. WHAT WILL THE READER GAIN: Insight into the complexity of treating patients with hypertensive nephropathy and the effective strategies required for reducing albuminuria, achieving BP goals and delaying progression of hypertensive nephropathy. TAKE HOME MESSAGE: Patients with hypertensive proteinuric nephropathy need aggressive BP-lowering with multiple agents that should include RAAS blockers, calcium antagonists and diuretics to maximally slow progression to ESRD. |
| | |
Authors:
|
Peter D Hart; George L Bakris |
Related Documents
:
|
10212348 - The clinical relevance of extreme dipping. 20977578 - Beyond ontarget: angiotensin-converting enzyme inhibition and angiotensin ii receptor b... 12119798 - The heart, kidney, and brain as target organs in hypertension. 11814138 - Improving the managed care of hypertension with angiotensin ii antagonists. 7512478 - The pathophysiology of hypertension. differences between young and elderly patients. 11324978 - Ocular complications of latanoprost in uveitic glaucoma: three case reports. |
Publication Detail:
|
Type: Journal Article Date: 2010-08-18 |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 11 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 2675-86 Citation Subset: IM |
Affiliation:
|
Cook County (Stroger) Hospital, Division of Nephrology, Department of Medicine, Chicago, IL 60612, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of size-resolved number concentrations of particulate matter with cardiovascular and res...
Next Document: Stroke prevention in atrial fibrillation patients.